drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00619 | DB11978 | 1,419 | 124 | [
"DDInter909",
"DDInter822"
] | Imatinib | Glasdegib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1419,
24,
124
]
],
[
[
1419,
25,
1135
],
[
1135,
23,
124
]
],
[
[
1419,
24,
466
],
[
466,
62,
124
]
],
[
[
1419,
24,
327
],
[
327,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a min... |
DB00553 | DB00850 | 92 | 1,630 | [
"DDInter1177",
"DDInter1432"
] | Methoxsalen | Perphenazine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
92,
24,
1630
]
],
[
[
92,
63,
508
],
[
508,
40,
1630
]
],
[
[
92,
24,
1178
],
[
1178,
40,
1630
]
],
[
[
92,
6,
7950
],
[
7950,
4... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Perphenazi... |
DB01259 | DB12095 | 392 | 179 | [
"DDInter1024",
"DDInter1760"
] | Lapatinib | Telotristat ethyl | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
392,
24,
179
]
],
[
[
392,
63,
79
],
[
79,
24,
179
]
],
[
[
392,
24,
310
],
[
310,
24,
179
]
],
[
[
392,
64,
1493
],
[
1493,
24,... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Ca... |
DB00635 | DB10675 | 1,573 | 961 | [
"DDInter1515",
"DDInter1065"
] | Prednisone | Licorice | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1573,
24,
961
]
],
[
[
1573,
40,
870
],
[
870,
24,
961
]
],
[
[
1573,
1,
891
],
[
891,
24,
961
]
],
[
[
1573,
24,
1231
],
[
1231,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a... | Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00986 | DB00999 | 1,192 | 504 | [
"DDInter834",
"DDInter883"
] | Glycopyrronium | Hydrochlorothiazide | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Minor | 0 | [
[
[
1192,
23,
504
]
],
[
[
1192,
23,
178
],
[
178,
1,
504
]
],
[
[
1192,
62,
323
],
[
323,
40,
504
]
],
[
[
1192,
23,
674
],
[
674,
... | [
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
... | Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compoun... |
DB00196 | DB06402 | 600 | 1,079 | [
"DDInter743",
"DDInter1756"
] | Fluconazole | Telavancin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
600,
24,
1079
]
],
[
[
600,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
600,
23,
112
],
[
112,
23,
1079
]
],
[
[
600,
24,
657
],
[
657,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v... | Fluconazole (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Fl... |
DB00407 | DB11703 | 202 | 405 | [
"DDInter115",
"DDInter9"
] | Ardeparin | Acalabrutinib | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
202,
25,
405
]
],
[
[
202,
24,
557
],
[
557,
24,
405
]
],
[
[
202,
24,
738
],
[
738,
63,
405
]
],
[
[
202,
25,
126
],
[
126,
25,... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deo... | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Nirapari... |
DB00398 | DB01138 | 79 | 804 | [
"DDInter1702",
"DDInter1726"
] | Sorafenib | Sulfinpyrazone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
79,
24,
804
]
],
[
[
79,
24,
998
],
[
998,
1,
804
]
],
[
[
79,
6,
3486
],
[
3486,
45,
804
]
],
[
[
79,
18,
7359
],
[
7359,
57,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Sorafenib (Compound) downregulates TXNDC9 (Gene) and... |
DB01200 | DB06691 | 469 | 849 | [
"DDInter243",
"DDInter1155"
] | Bromocriptine | Mepyramine | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
469,
24,
849
]
],
[
[
469,
63,
1594
],
[
1594,
24,
849
]
],
[
[
469,
7,
2216
],
[
2216,
46,
849
]
],
[
[
469,
24,
407
],
[
407,
... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Mepyramine (Compound)
Brom... |
DB00317 | DB00357 | 883 | 1,051 | [
"DDInter810",
"DDInter71"
] | Gefitinib | Aminoglutethimide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Moderate | 1 | [
[
[
883,
24,
1051
]
],
[
[
883,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
883,
21,
28803
],
[
28803,
60,
1051
]
],
[
[
883,
63,
1101
],
[
1101,... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Gefitinib (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Aminoglutethimide (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene a... |
DB00494 | DB01069 | 1,533 | 401 | [
"DDInter646",
"DDInter1533"
] | Entacapone | Promethazine | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1533,
24,
401
]
],
[
[
1533,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1533,
24,
104
],
[
104,
24,
401
]
],
[
[
1533,
21,
28709
],
[
28709,... | [
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB01149 | DB09330 | 851 | 985 | [
"DDInter1274",
"DDInter1352"
] | Nefazodone | Osimertinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
851,
25,
985
]
],
[
[
851,
63,
168
],
[
168,
23,
985
]
],
[
[
851,
25,
1478
],
[
1478,
24,
985
]
],
[
[
851,
64,
134
],
[
134,
2... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomi... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Nefazodone may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a m... |
DB01267 | DB11901 | 519 | 913 | [
"DDInter1381",
"DDInter107"
] | Paliperidone | Apalutamide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
519,
24,
913
]
],
[
[
519,
62,
112
],
[
112,
23,
913
]
],
[
[
519,
63,
600
],
[
600,
24,
913
]
],
[
[
519,
24,
28
],
[
28,
24,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole an... |
DB00281 | DB00754 | 608 | 157 | [
"DDInter1066",
"DDInter696"
] | Lidocaine | Ethotoin | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Minor | 0 | [
[
[
608,
23,
157
]
],
[
[
608,
23,
759
],
[
759,
40,
157
]
],
[
[
608,
6,
11001
],
[
11001,
45,
157
]
],
[
[
608,
18,
15501
],
[
15501,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
],
[
"Prim... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Lidocaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Ethotoin (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downre... |
DB00060 | DB09061 | 912 | 1,627 | [
"DDInter947",
"DDInter284"
] | Interferon beta-1a | Cannabidiol | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
912,
24,
1627
]
],
[
[
912,
24,
609
],
[
609,
23,
1627
]
],
[
[
912,
24,
351
],
[
351,
62,
1627
]
],
[
[
912,
24,
888
],
[
888,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithrom... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01191 | DB06700 | 1,039 | 643 | [
"DDInter518",
"DDInter511"
] | Dexfenfluramine | Desvenlafaxine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Major | 2 | [
[
[
1039,
25,
643
]
],
[
[
1039,
64,
1100
],
[
1100,
1,
643
]
],
[
[
1039,
6,
6112
],
[
6112,
45,
643
]
],
[
[
1039,
24,
1383
],
[
1383,
... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxin... | Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Dexfenfluramine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Desvenlafaxine (Compound)
Dexfenfluramine may cause a moderate interaction that could e... |
DB00719 | DB06282 | 1,219 | 516 | [
"DDInter149",
"DDInter1053"
] | Azatadine | Levocetirizine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1219,
24,
516
]
],
[
[
1219,
23,
771
],
[
771,
62,
516
]
],
[
[
1219,
24,
1074
],
[
1074,
63,
516
]
],
[
[
1219,
63,
701
],
[
701,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[... | Azatadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and ... |
DB01138 | DB12267 | 804 | 1,476 | [
"DDInter1726",
"DDInter233"
] | Sulfinpyrazone | Brigatinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
804,
24,
1476
]
],
[
[
804,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
804,
62,
168
],
[
168,
23,
1476
]
],
[
[
804,
63,
629
],
[
629,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bort... |
DB01097 | DB01235 | 1,377 | 1,191 | [
"DDInter1033",
"DDInter1054"
] | Leflunomide | Levodopa | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1377,
24,
1191
]
],
[
[
1377,
64,
1307
],
[
1307,
40,
1191
]
],
[
[
1377,
64,
1551
],
[
1551,
1,
1191
]
],
[
[
1377,
21,
28936
],
[
28... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",... | Leflunomide may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Methyldopa and Methyldopa (Compound) resembles Levodopa (Compound)
Leflunomide (Compound) causes Hype... |
DB00436 | DB00855 | 323 | 213 | [
"DDInter179",
"DDInter72"
] | Bendroflumethiazide | Aminolevulinic acid | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
323,
25,
213
]
],
[
[
323,
21,
28766
],
[
28766,
60,
213
]
],
[
[
323,
40,
1577
],
[
1577,
25,
213
]
],
[
[
323,
40,
504
],
[
504,
... | [
[
[
"Bendroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side... | Bendroflumethiazide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Aminolevulinic acid (Compound)
Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Ben... |
DB00712 | DB12332 | 1,274 | 1,619 | [
"DDInter763",
"DDInter1626"
] | Flurbiprofen | Rucaparib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1274,
24,
1619
]
],
[
[
1274,
24,
222
],
[
222,
23,
1619
]
],
[
[
1274,
63,
84
],
[
84,
24,
1619
]
],
[
[
1274,
24,
1662
],
[
1662,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Ni... |
DB00407 | DB05773 | 202 | 1,047 | [
"DDInter115",
"DDInter1848"
] | Ardeparin | Trastuzumab emtansine | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
202,
25,
1047
]
],
[
[
202,
25,
848
],
[
848,
24,
1047
]
],
[
[
202,
24,
222
],
[
222,
24,
1047
]
],
[
[
202,
63,
1560
],
[
1560,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
... | Ardeparin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine m... |
DB00444 | DB01174 | 63 | 697 | [
"DDInter1765",
"DDInter1442"
] | Teniposide | Phenobarbital | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
63,
24,
697
]
],
[
[
63,
24,
759
],
[
759,
1,
697
]
],
[
[
63,
63,
362
],
[
362,
1,
697
]
],
[
[
63,
6,
6017
],
[
6017,
45,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound... |
DB01030 | DB06176 | 869 | 1,342 | [
"DDInter1835",
"DDInter1616"
] | Topotecan | Romidepsin | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
869,
24,
1342
]
],
[
[
869,
23,
956
],
[
956,
24,
1342
]
],
[
[
869,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
869,
63,
51
],
[
51,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
... | Topotecan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midosta... |
DB01225 | DB10344 | 500 | 992 | [
"DDInter645",
"DDInter818"
] | Enoxaparin | Ginger | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
500,
24,
992
]
],
[
[
500,
64,
1578
],
[
1578,
24,
992
]
],
[
[
500,
25,
1421
],
[
1421,
63,
992
]
],
[
[
500,
25,
802
],
[
802,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
... | Enoxaparin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interactio... |
DB00637 | DB12267 | 1,557 | 1,476 | [
"DDInter128",
"DDInter233"
] | Astemizole | Brigatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1557,
24,
1476
]
],
[
[
1557,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1557,
24,
629
],
[
629,
24,
1476
]
],
[
[
1557,
63,
79
],
[
79,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolim... |
DB12095 | DB12500 | 179 | 283 | [
"DDInter1760",
"DDInter714"
] | Telotristat ethyl | Fedratinib | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
179,
24,
283
]
],
[
[
179,
24,
466
],
[
466,
62,
283
]
],
[
[
179,
63,
351
],
[
351,
23,
283
]
],
[
[
179,
63,
1419
],
[
1419,
2... | [
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"... | Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Riboc... |
DB00227 | DB11718 | 1,463 | 927 | [
"DDInter1098",
"DDInter640"
] | Lovastatin | Encorafenib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1463,
24,
927
]
],
[
[
1463,
24,
112
],
[
112,
23,
927
]
],
[
[
1463,
24,
372
],
[
372,
24,
927
]
],
[
[
1463,
63,
1324
],
[
1324,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and ... |
DB00549 | DB00773 | 522 | 896 | [
"DDInter1955",
"DDInter702"
] | Zafirlukast | Etoposide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
522,
24,
896
]
],
[
[
522,
6,
3486
],
[
3486,
45,
896
]
],
[
[
522,
21,
28681
],
[
28681,
60,
896
]
],
[
[
522,
23,
307
],
[
307,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Zafirlukast (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Etoposide (Compound)
Zafirlukast (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Modafi... |
DB00346 | DB01259 | 472 | 392 | [
"DDInter44",
"DDInter1024"
] | Alfuzosin | Lapatinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
472,
24,
392
]
],
[
[
472,
6,
8374
],
[
8374,
45,
392
]
],
[
[
472,
21,
29429
],
[
29429,
60,
392
]
],
[
[
472,
23,
112
],
[
112,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Alfuzosin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB01064 | DB06203 | 1,148 | 1,002 | [
"DDInter987",
"DDInter51"
] | Isoprenaline | Alogliptin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1148,
24,
1002
]
],
[
[
1148,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1148,
21,
28762
],
[
28762,
60,
1002
]
],
[
[
1148,
24,
401
],
[
4... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Alogliptin (Compound)
Isoprenaline may cause a moderate intera... |
DB00060 | DB00939 | 912 | 1,338 | [
"DDInter947",
"DDInter1135"
] | Interferon beta-1a | Meclofenamic acid | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
912,
24,
1338
]
],
[
[
912,
24,
850
],
[
850,
63,
1338
]
],
[
[
912,
24,
482
],
[
482,
24,
1338
]
],
[
[
912,
63,
305
],
[
305,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bren... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate disea... |
DB09237 | DB09333 | 1,586 | 278 | [
"DDInter1045",
"DDInter963"
] | Levamlodipine | Iopodic acid | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
1586,
24,
278
]
],
[
[
1586,
63,
1648
],
[
1648,
24,
278
]
],
[
[
1586,
63,
1648
],
[
1648,
24,
461
],
[
461,
24,
278
]
],
[
[
1586,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],... | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin... |
DB00346 | DB09080 | 472 | 144 | [
"DDInter44",
"DDInter1331"
] | Alfuzosin | Olodaterol | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
472,
24,
144
]
],
[
[
472,
25,
1011
],
[
1011,
24,
144
]
],
[
[
472,
24,
543
],
[
543,
24,
144
]
],
[
[
472,
63,
600
],
[
600,
2... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Alfuzosin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a ... |
DB00860 | DB01232 | 891 | 1,327 | [
"DDInter1513",
"DDInter1640"
] | Prednisolone | Saquinavir | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
891,
24,
1327
]
],
[
[
891,
63,
798
],
[
798,
40,
1327
]
],
[
[
891,
24,
915
],
[
915,
40,
1327
]
],
[
[
891,
6,
6648
],
[
6648,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compou... |
DB04855 | DB09049 | 540 | 1,135 | [
"DDInter602",
"DDInter1261"
] | Dronedarone | Naloxegol | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
540,
25,
1135
]
],
[
[
540,
1,
33
],
[
33,
23,
1135
]
],
[
[
540,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
540,
64,
1424
],
[
1424,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a minor interaction tha... | Dronedarone (Compound) resembles Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects... |
DB00834 | DB11718 | 932 | 927 | [
"DDInter1215",
"DDInter640"
] | Mifepristone | Encorafenib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
932,
25,
927
]
],
[
[
932,
23,
112
],
[
112,
23,
927
]
],
[
[
932,
24,
720
],
[
720,
24,
927
]
],
[
[
932,
63,
1324
],
[
1324,
2... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB00342 | DB08903 | 1,181 | 996 | [
"DDInter1770",
"DDInter170"
] | Terfenadine | Bedaquiline | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1181,
25,
996
]
],
[
[
1181,
23,
112
],
[
112,
23,
996
]
],
[
[
1181,
24,
355
],
[
355,
24,
996
]
],
[
[
1181,
24,
144
],
[
144,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and La... |
DB00363 | DB11837 | 695 | 1,297 | [
"DDInter419",
"DDInter1351"
] | Clozapine | Osilodrostat | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
695,
25,
1297
]
],
[
[
695,
23,
112
],
[
112,
23,
1297
]
],
[
[
695,
24,
222
],
[
222,
23,
1297
]
],
[
[
695,
1,
623
],
[
623,
2... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sib... |
DB01210 | DB09080 | 668 | 144 | [
"DDInter1050",
"DDInter1331"
] | Levobunolol (ophthalmic) | Olodaterol | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Major | 2 | [
[
[
668,
25,
144
]
],
[
[
668,
24,
1011
],
[
1011,
24,
144
]
],
[
[
668,
64,
455
],
[
455,
24,
144
]
],
[
[
668,
63,
1148
],
[
1148,
... | [
[
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolim... | Levobunolol may lead to a major life threatening interaction when taken with Olodaterol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol may lead to... |
DB00218 | DB00987 | 1,176 | 1,224 | [
"DDInter1247",
"DDInter460"
] | Moxifloxacin | Cytarabine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Minor | 0 | [
[
[
1176,
23,
1224
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
1224
]
],
[
[
1176,
1,
872
],
[
872,
62,
1224
]
],
[
[
1176,
1,
739
],
[
739,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Com... | Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Cytarabine (Compound)
Moxifloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Moxifloxacin (Compound) resembles Lomefloxacin (Compou... |
DB00290 | DB01610 | 329 | 248 | [
"DDInter219",
"DDInter1912"
] | Bleomycin | Valganciclovir | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
329,
24,
248
]
],
[
[
329,
24,
563
],
[
563,
1,
248
]
],
[
[
329,
21,
29209
],
[
29209,
60,
248
]
],
[
[
329,
24,
1238
],
[
1238,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Bleomycin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Bleomycin may cause a moderate interac... |
DB00169 | DB01045 | 386 | 463 | [
"DDInter367",
"DDInter1590"
] | Cholecalciferol | Rifampicin | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
386,
24,
463
]
],
[
[
386,
24,
690
],
[
690,
40,
463
]
],
[
[
386,
6,
10215
],
[
10215,
45,
463
]
],
[
[
386,
25,
1196
],
[
1196,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Cholecalciferol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Cholecalciferol may lead to a major life threatening int... |
DB06824 | DB09104 | 29 | 286 | [
"DDInter1864",
"DDInter1118"
] | Triethylenetetramine | Magnesium hydroxide | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
29,
24,
286
]
],
[
[
29,
63,
954
],
[
954,
23,
286
]
],
[
[
29,
63,
1283
],
[
1283,
24,
286
]
],
[
[
29,
24,
428
],
[
428,
63,
... | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00224 | DB04868 | 215 | 478 | [
"DDInter917",
"DDInter1293"
] | Indinavir | Nilotinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
215,
25,
478
]
],
[
[
215,
25,
1468
],
[
1468,
63,
478
]
],
[
[
215,
6,
6017
],
[
6017,
45,
478
]
],
[
[
215,
18,
10375
],
[
10375,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may ca... | Indinavir may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Indinavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Indinavir (Compound) downregulates RPS4... |
DB00195 | DB00938 | 726 | 455 | [
"DDInter198",
"DDInter1635"
] | Betaxolol (ophthalmic) | Salmeterol | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
726,
24,
455
]
],
[
[
726,
24,
688
],
[
688,
63,
455
]
],
[
[
726,
6,
3576
],
[
3576,
45,
455
]
],
[
[
726,
21,
29095
],
[
29095,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol (C... |
DB06691 | DB14509 | 849 | 1,399 | [
"DDInter1155",
"DDInter1081"
] | Mepyramine | Lithium carbonate | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
849,
24,
1399
]
],
[
[
849,
63,
506
],
[
506,
24,
1399
]
],
[
[
849,
24,
407
],
[
407,
24,
1399
]
],
[
[
849,
74,
100
],
[
100,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Op... |
DB01267 | DB09045 | 519 | 52 | [
"DDInter1381",
"DDInter607"
] | Paliperidone | Dulaglutide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
519,
24,
52
]
],
[
[
519,
63,
170
],
[
170,
23,
52
]
],
[
[
519,
63,
609
],
[
609,
24,
52
]
],
[
[
519,
25,
1154
],
[
1154,
24,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB01406 | DB06203 | 984 | 1,002 | [
"DDInter472",
"DDInter51"
] | Danazol | Alogliptin | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
984,
24,
1002
]
],
[
[
984,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
984,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
984,
21,
28873
],
[
28873,... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"... | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Danazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Danazol (Compound) causes Pancreatitis (Side Effect) and Pancreatitis ... |
DB01069 | DB08824 | 401 | 591 | [
"DDInter1533",
"DDInter959"
] | Promethazine | Ioflupane I-123 | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
401,
24,
591
]
],
[
[
401,
21,
28762
],
[
28762,
60,
591
]
],
[
[
401,
63,
109
],
[
109,
24,
591
]
],
[
[
401,
25,
924
],
[
924,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) ... | Promethazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ioflupane I-123 (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00163 | DB11988 | 1,461 | 270 | [
"DDInter1943",
"DDInter1321"
] | Vitamin E | Ocrelizumab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Minor | 0 | [
[
[
1461,
23,
270
]
],
[
[
1461,
24,
134
],
[
134,
24,
270
]
],
[
[
1461,
23,
1019
],
[
1019,
24,
270
]
],
[
[
1461,
62,
1309
],
[
1309,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Deflazacort and Deflaz... |
DB06176 | DB08827 | 1,342 | 990 | [
"DDInter1616",
"DDInter1085"
] | Romidepsin | Lomitapide | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1342,
24,
990
]
],
[
[
1342,
63,
1080
],
[
1080,
1,
990
]
],
[
[
1342,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1342,
63,
77
],
[
77,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exa... |
DB00653 | DB00910 | 544 | 1,041 | [
"DDInter1120",
"DDInter1394"
] | Magnesium sulfate | Paricalcitol | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
544,
24,
1041
]
],
[
[
544,
63,
386
],
[
386,
25,
1041
]
],
[
[
544,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
544,
21,
29263
],
[
29263,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalcif... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotac... |
DB00060 | DB08903 | 912 | 996 | [
"DDInter947",
"DDInter170"
] | Interferon beta-1a | Bedaquiline | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
912,
24,
996
]
],
[
[
912,
24,
713
],
[
713,
63,
996
]
],
[
[
912,
24,
848
],
[
848,
24,
996
]
],
[
[
912,
25,
593
],
[
593,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl f... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when t... |
DB06176 | DB08904 | 1,342 | 375 | [
"DDInter1616",
"DDInter342"
] | Romidepsin | Certolizumab pegol | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1342,
25,
375
]
],
[
[
1342,
63,
1461
],
[
1461,
23,
375
]
],
[
[
1342,
24,
200
],
[
200,
63,
375
]
],
[
[
1342,
25,
1593
],
[
1593,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vit... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans ... |
DB00424 | DB08815 | 19 | 154 | [
"DDInter896",
"DDInter1104"
] | Hyoscyamine | Lurasidone | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
19,
24,
154
]
],
[
[
19,
21,
28963
],
[
28963,
60,
154
]
],
[
[
19,
24,
100
],
[
100,
24,
154
]
],
[
[
19,
63,
999
],
[
999,
24,... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused... | Hyoscyamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00559 | DB09143 | 152 | 313 | [
"DDInter223",
"DDInter1701"
] | Bosentan | Sonidegib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
152,
25,
313
]
],
[
[
152,
24,
478
],
[
478,
24,
313
]
],
[
[
152,
25,
484
],
[
484,
63,
313
]
],
[
[
152,
24,
1320
],
[
1320,
6... | [
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a mod... |
DB00361 | DB06717 | 134 | 875 | [
"DDInter1939",
"DDInter778"
] | Vinorelbine | Fosaprepitant | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
134,
24,
875
]
],
[
[
134,
24,
723
],
[
723,
1,
875
]
],
[
[
134,
21,
29122
],
[
29122,
60,
875
]
],
[
[
134,
63,
1101
],
[
1101,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Vinorelbine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Vinorelbine ma... |
DB00533 | DB08816 | 1,416 | 578 | [
"DDInter1613",
"DDInter1802"
] | Rofecoxib | Ticagrelor | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1416,
24,
578
]
],
[
[
1416,
63,
1578
],
[
1578,
24,
578
]
],
[
[
1416,
24,
1220
],
[
1220,
24,
578
]
],
[
[
1416,
24,
840
],
[
840,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamet... |
DB00872 | DB11837 | 1,080 | 1,297 | [
"DDInter438",
"DDInter1351"
] | Conivaptan | Osilodrostat | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1080,
25,
1297
]
],
[
[
1080,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
1080,
24,
466
],
[
466,
62,
1297
]
],
[
[
1080,
24,
222
],
[
222,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Conivaptan may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
DB00401 | DB01041 | 84 | 770 | [
"DDInter1298",
"DDInter1789"
] | Nisoldipine | Thalidomide | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
84,
24,
770
]
],
[
[
84,
6,
7524
],
[
7524,
45,
770
]
],
[
[
84,
7,
7669
],
[
7669,
46,
770
]
],
[
[
84,
21,
29598
],
[
29598,
6... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Nisoldipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Nisoldipine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Nisoldipine (Compound) causes Cellulitis (Side Effect) and Cellulitis (Side Effect) is caused by Thalidomide (Compound... |
DB01176 | DB01181 | 537 | 1,532 | [
"DDInter453",
"DDInter906"
] | Cyclizine | Ifosfamide | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
537,
24,
1532
]
],
[
[
537,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
537,
18,
5415
],
[
5415,
46,
1532
]
],
[
[
537,
21,
28666
],
[
28666,... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Cyclizine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Cyclizine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound)
Cyclizine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by... |
DB00795 | DB08881 | 50 | 868 | [
"DDInter1725",
"DDInter1925"
] | Sulfasalazine | Vemurafenib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
50,
24,
868
]
],
[
[
50,
6,
17404
],
[
17404,
45,
868
]
],
[
[
50,
6,
16740
],
[
16740,
46,
868
]
],
[
[
50,
7,
7273
],
[
7273,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compou... | Sulfasalazine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vemurafenib (Compound)
Sulfasalazine (Compound) binds SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Vemurafenib (Compound)
Sulfasalazine (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Vemurafenib (Compound)
Sulfas... |
DB05015 | DB06636 | 1,077 | 1,623 | [
"DDInter174",
"DDInter980"
] | Belinostat | Isavuconazonium | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1077,
24,
1623
]
],
[
[
1077,
24,
1250
],
[
1250,
24,
1623
]
],
[
[
1077,
24,
214
],
[
214,
63,
1623
]
],
[
[
1077,
63,
869
],
[
869,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and F... |
DB00526 | DB12834 | 1,555 | 148 | [
"DDInter1355",
"DDInter1649"
] | Oxaliplatin | Secnidazole | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
1555,
24,
148
]
],
[
[
1555,
25,
1593
],
[
1593,
24,
148
]
],
[
[
1555,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1555,
63,
597
],
[
597,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizoti... | Oxaliplatin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a... |
DB00193 | DB12141 | 534 | 971 | [
"DDInter1841",
"DDInter817"
] | Tramadol | Gilteritinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
534,
24,
971
]
],
[
[
534,
23,
112
],
[
112,
23,
971
]
],
[
[
534,
24,
485
],
[
485,
24,
971
]
],
[
[
534,
1,
1100
],
[
1100,
24... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Penta... |
DB00682 | DB01326 | 126 | 1,124 | [
"DDInter1951",
"DDInter312"
] | Warfarin | Cefamandole | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States. | Moderate | 1 | [
[
[
126,
24,
1124
]
],
[
[
126,
24,
1305
],
[
1305,
1,
1124
]
],
[
[
126,
24,
665
],
[
665,
40,
1124
]
],
[
[
126,
63,
164
],
[
164,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
],
[
"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefamandole (Compound)
Warfar... |
DB06372 | DB09054 | 259 | 384 | [
"DDInter1594",
"DDInter905"
] | Rilonacept | Idelalisib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
259,
24,
384
]
],
[
[
259,
25,
725
],
[
725,
63,
384
]
],
[
[
259,
63,
328
],
[
328,
24,
384
]
],
[
[
259,
24,
287
],
[
287,
63,... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satraliz... | Rilonacept may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurin... |
DB00976 | DB12245 | 1,056 | 823 | [
"DDInter1758",
"DDInter1863"
] | Telithromycin | Triclabendazole | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1056,
24,
823
]
],
[
[
1056,
62,
112
],
[
112,
23,
823
]
],
[
[
1056,
63,
1010
],
[
1010,
24,
823
]
],
[
[
1056,
24,
28
],
[
28,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mefloqui... |
DB06626 | DB08899 | 263 | 129 | [
"DDInter147",
"DDInter649"
] | Axitinib | Enzalutamide | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
263,
25,
129
]
],
[
[
263,
63,
918
],
[
918,
1,
129
]
],
[
[
263,
25,
1510
],
[
1510,
24,
129
]
],
[
[
263,
64,
851
],
[
851,
24... | [
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutami... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Axitinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacer... |
DB00220 | DB06655 | 798 | 5 | [
"DDInter1276",
"DDInter1077"
] | Nelfinavir | Liraglutide | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
798,
24,
5
]
],
[
[
798,
24,
353
],
[
353,
23,
5
]
],
[
[
798,
24,
1142
],
[
1142,
24,
5
]
],
[
[
798,
63,
176
],
[
176,
24,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlis... |
DB01320 | DB04845 | 651 | 309 | [
"DDInter783",
"DDInter1001"
] | Fosphenytoin | Ixabepilone | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
651,
24,
309
]
],
[
[
651,
6,
8374
],
[
8374,
45,
309
]
],
[
[
651,
21,
28736
],
[
28736,
60,
309
]
],
[
[
651,
63,
60
],
[
60,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Fosphenytoin (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Capecit... |
DB00347 | DB00405 | 917 | 128 | [
"DDInter1871",
"DDInter517"
] | Trimethadione | Dexbrompheniramine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
917,
24,
128
]
],
[
[
917,
24,
662
],
[
662,
63,
128
]
],
[
[
917,
63,
475
],
[
475,
24,
128
]
],
[
[
917,
24,
1594
],
[
1594,
3... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine... | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB00308 | DB01177 | 347 | 77 | [
"DDInter901",
"DDInter904"
] | Ibutilide | Idarubicin | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
347,
25,
77
]
],
[
[
347,
21,
29170
],
[
29170,
60,
77
]
],
[
[
347,
23,
112
],
[
112,
23,
77
]
],
[
[
347,
25,
823
],
[
823,
63... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Sid... | Ibutilide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Idarubicin (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinic... |
DB00277 | DB00938 | 1,031 | 455 | [
"DDInter1791",
"DDInter1635"
] | Theophylline | Salmeterol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1031,
24,
455
]
],
[
[
1031,
25,
1523
],
[
1523,
25,
455
]
],
[
[
1031,
24,
688
],
[
688,
63,
455
]
],
[
[
1031,
5,
11649
],
[
11649,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetal... | Theophylline may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate in... |
DB00816 | DB01576 | 1,674 | 93 | [
"DDInter1346",
"DDInter526"
] | Orciprenaline | Dextroamphetamine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
1674,
24,
93
]
],
[
[
1674,
63,
73
],
[
73,
1,
93
]
],
[
[
1674,
63,
80
],
[
80,
40,
93
]
],
[
[
1674,
24,
1529
],
[
1529,
40,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Dextr... |
DB00802 | DB01168 | 1,322 | 1,053 | [
"DDInter43",
"DDInter1526"
] | Alfentanil | Procarbazine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1322,
25,
1053
]
],
[
[
1322,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1322,
24,
100
],
[
100,
24,
1053
]
],
[
[
1322,
24,
830
],
[
830... | [
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Comp... | Alfentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB04868 | DB06717 | 478 | 875 | [
"DDInter1293",
"DDInter778"
] | Nilotinib | Fosaprepitant | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
478,
24,
875
]
],
[
[
478,
63,
723
],
[
723,
1,
875
]
],
[
[
478,
21,
29180
],
[
29180,
60,
875
]
],
[
[
478,
63,
222
],
[
222,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Nilotinib (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Nilotinib may caus... |
DB00468 | DB01072 | 1,424 | 915 | [
"DDInter1557",
"DDInter129"
] | Quinine | Atazanavir | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
1424,
24,
915
]
],
[
[
1424,
25,
1327
],
[
1327,
1,
915
]
],
[
[
1424,
6,
4973
],
[
4973,
45,
915
]
],
[
[
1424,
21,
28642
],
[
28642,... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
... | Quinine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Quinine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Quinine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Atazan... |
DB00490 | DB09280 | 946 | 1,604 | [
"DDInter254",
"DDInter1101"
] | Buspirone | Lumacaftor | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
946,
25,
1604
]
],
[
[
946,
24,
629
],
[
629,
25,
1604
]
],
[
[
946,
24,
159
],
[
159,
64,
1604
]
],
[
[
946,
24,
629
],
[
629,
... | [
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead... |
DB00747 | DB00909 | 1,442 | 306 | [
"DDInter1647",
"DDInter1971"
] | Scopolamine | Zonisamide | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
1442,
25,
306
]
],
[
[
1442,
21,
28691
],
[
28691,
60,
306
]
],
[
[
1442,
24,
407
],
[
407,
63,
306
]
],
[
[
1442,
63,
475
],
[
475,
... | [
[
[
"Scopolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (... | Scopolamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Sc... |
DB00163 | DB00515 | 1,461 | 589 | [
"DDInter1943",
"DDInter387"
] | Vitamin E | Cisplatin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
1461,
24,
589
]
],
[
[
1461,
6,
2490
],
[
2490,
45,
589
]
],
[
[
1461,
62,
58
],
[
58,
24,
589
]
],
[
[
1461,
24,
168
],
[
168,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"NQO1"
],
[
"NQO1",
"{u} (Gene) is bound by {v} (Compound)",
... | Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Cisplatin (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a moderate... |
DB11986 | DB14723 | 484 | 159 | [
"DDInter648",
"DDInter1026"
] | Entrectinib | Larotrectinib | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
484,
24,
159
]
],
[
[
484,
62,
222
],
[
222,
23,
159
]
],
[
[
484,
23,
907
],
[
907,
23,
159
]
],
[
[
484,
63,
479
],
[
479,
23,... | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Dorav... |
DB00241 | DB00341 | 288 | 1,242 | [
"DDInter257",
"DDInter343"
] | Butalbital | Cetirizine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
288,
24,
1242
]
],
[
[
288,
24,
1031
],
[
1031,
23,
1242
]
],
[
[
288,
25,
475
],
[
475,
24,
1242
]
],
[
[
288,
24,
1614
],
[
1614,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Cetirizine
Butalbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a ... |
DB08816 | DB11793 | 578 | 738 | [
"DDInter1802",
"DDInter1297"
] | Ticagrelor | Niraparib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
578,
24,
738
]
],
[
[
578,
64,
1213
],
[
1213,
24,
738
]
],
[
[
578,
63,
1578
],
[
1578,
24,
738
]
],
[
[
578,
24,
1619
],
[
1619,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a mod... |
DB06616 | DB12161 | 594 | 730 | [
"DDInter224",
"DDInter512"
] | Bosutinib | Deutetrabenazine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
594,
24,
730
]
],
[
[
594,
62,
112
],
[
112,
23,
730
]
],
[
[
594,
63,
1559
],
[
1559,
24,
730
]
],
[
[
594,
24,
971
],
[
971,
2... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and ... |
DB01067 | DB01144 | 959 | 1,326 | [
"DDInter826",
"DDInter540"
] | Glipizide | Diclofenamide | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
959,
24,
1326
]
],
[
[
959,
63,
504
],
[
504,
1,
1326
]
],
[
[
959,
63,
359
],
[
359,
40,
1326
]
],
[
[
959,
6,
6017
],
[
6017,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resem... |
DB00845 | DB09104 | 1,490 | 286 | [
"DDInter406",
"DDInter1118"
] | Clofazimine | Magnesium hydroxide | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1490,
24,
286
]
],
[
[
1490,
24,
820
],
[
820,
23,
286
]
],
[
[
1490,
63,
355
],
[
355,
23,
286
]
],
[
[
1490,
24,
688
],
[
688,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose ... |
DB01005 | DB10343 | 995 | 962 | [
"DDInter894",
"DDInter160"
] | Hydroxyurea | Bacillus calmette-guerin substrain tice live antigen | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
995,
25,
962
]
],
[
[
995,
64,
1057
],
[
1057,
25,
962
]
],
[
[
995,
24,
270
],
[
270,
64,
962
]
],
[
[
995,
63,
663
],
[
663,
2... | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Hydroxyurea may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Ocreliz... |
DB01072 | DB08907 | 915 | 1,344 | [
"DDInter129",
"DDInter280"
] | Atazanavir | Canagliflozin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
915,
24,
1344
]
],
[
[
915,
24,
549
],
[
549,
1,
1344
]
],
[
[
915,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
915,
21,
28873
],
[
28873,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Atazanavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Atazanavir (Compound) causes Pancreatitis (Side Effect) ... |
DB01211 | DB01396 | 609 | 1,482 | [
"DDInter393",
"DDInter553"
] | Clarithromycin | Digitoxin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
609,
24,
1482
]
],
[
[
609,
64,
1252
],
[
1252,
1,
1482
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
609,
18,
9579
],
[
9579,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digoxi... | Clarithromycin may lead to a major life threatening interaction when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Clarithromycin (Compound) downregulates PDHX (Gene) and PDHX (Gene) is upregulate... |
DB00450 | DB00748 | 78 | 662 | [
"DDInter603",
"DDInter297"
] | Droperidol | Carbinoxamine | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
78,
24,
662
]
],
[
[
78,
24,
28
],
[
28,
40,
662
]
],
[
[
78,
63,
1594
],
[
1594,
24,
662
]
],
[
[
78,
21,
28921
],
[
28921,
60,... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that coul... |
DB01073 | DB01229 | 1,488 | 973 | [
"DDInter745",
"DDInter1378"
] | Fludarabine | Paclitaxel (protein-bound) | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1488,
24,
973
]
],
[
[
1488,
24,
310
],
[
310,
63,
973
]
],
[
[
1488,
21,
28643
],
[
28643,
60,
973
]
],
[
[
1488,
23,
945
],
[
945,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludar... |
DB00543 | DB00938 | 87 | 455 | [
"DDInter82",
"DDInter1635"
] | Amoxapine | Salmeterol | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
87,
24,
455
]
],
[
[
87,
24,
688
],
[
688,
63,
455
]
],
[
[
87,
7,
9650
],
[
9650,
46,
455
]
],
[
[
87,
21,
29024
],
[
29024,
60... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Salmeterol (Compound)
Amoxapin... |
DB00222 | DB09082 | 245 | 659 | [
"DDInter825",
"DDInter1934"
] | Glimepiride | Vilanterol | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
245,
24,
659
]
],
[
[
245,
24,
1220
],
[
1220,
23,
659
]
],
[
[
245,
24,
1296
],
[
1296,
63,
659
]
],
[
[
245,
24,
88
],
[
88,
2... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglude... |
DB00848 | DB04865 | 281 | 4 | [
"DDInter1044",
"DDInter1335"
] | Levamisole | Omacetaxine mepesuccinate | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
281,
24,
4
]
],
[
[
281,
24,
496
],
[
496,
63,
4
]
],
[
[
281,
63,
208
],
[
208,
24,
4
]
],
[
[
281,
24,
563
],
[
563,
24,
... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A ... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when... |
DB00421 | DB08907 | 443 | 1,344 | [
"DDInter1707",
"DDInter280"
] | Spironolactone | Canagliflozin | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
443,
24,
1344
]
],
[
[
443,
24,
549
],
[
549,
1,
1344
]
],
[
[
443,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
443,
21,
28962
],
[
28962,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Spironolactone (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Spironolactone (Compound) causes Hyperkalaemia (... |
DB00404 | DB00792 | 523 | 832 | [
"DDInter54",
"DDInter1878"
] | Alprazolam | Tripelennamine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
523,
24,
832
]
],
[
[
523,
24,
100
],
[
100,
63,
832
]
],
[
[
523,
24,
649
],
[
649,
1,
832
]
],
[
[
523,
63,
1594
],
[
1594,
24... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clofeda... |
DB01082 | DB01413 | 1,448 | 1,403 | [
"DDInter1713",
"DDInter317"
] | Streptomycin | Cefepime | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections ca... | Moderate | 1 | [
[
[
1448,
24,
1403
]
],
[
[
1448,
24,
1024
],
[
1024,
40,
1403
]
],
[
[
1448,
24,
731
],
[
731,
1,
1403
]
],
[
[
1448,
63,
1087
],
[
1087,... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
],
[... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime and Cefpodoxime (Compound) resembles Cefepime (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftizoxime and Ceftizoxime (Compound) resembles Cefepime (Compou... |
DB06691 | DB11823 | 849 | 858 | [
"DDInter1155",
"DDInter673"
] | Mepyramine | Esketamine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Moderate | 1 | [
[
[
849,
24,
858
]
],
[
[
849,
63,
272
],
[
272,
24,
858
]
],
[
[
849,
74,
100
],
[
100,
24,
858
]
],
[
[
849,
24,
1609
],
[
1609,
2... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate inter... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.